Pharma & drug development · Reference
What is a generic drug?
A generic drug is a medicine that contains the same active ingredient as an approved brand-name product and is shown to be bioequivalent to it. Generics typically reach the market after the original’s patents expire, via an abbreviated FDA application.
What makes a drug “generic”
A generic is built around the same active pharmaceutical ingredient as its brand-name reference, delivered in the same strength, dosage form and route of administration. It need not be identical in every respect — inactive ingredients (excipients), shape or colour may differ — but it must perform the same way in the body. The defining requirement is bioequivalence: the generic must deliver the active ingredient to the bloodstream at a comparable rate and extent, so its bioavailability matches that of the reference within accepted limits. This is a regulatory and scientific definition, not a recommendation to use any particular product.
The ANDA pathway
Generics reach the market through an Abbreviated New Drug Application (ANDA), a streamlined route the FDA reviews. It is “abbreviated” because the applicant does not repeat the full programme of safety and efficacy clinical trials the original required; the reference product already established that the active ingredient is safe and effective. Instead, the applicant demonstrates that its product is the same in the ways that matter and is bioequivalent. The manufacturer must still meet Good Manufacturing Practice and quality standards, so an approved generic is held to the same manufacturing rigour as a brand product.
Patents, competition and why generics exist
Generics generally appear only after the brand product’s patents and regulatory exclusivity have expired. During that protected period the original developer can market without generic competition, which helps it recoup the investment of drug development. Once protection lapses, others may seek approval to make the same medicine.
Because generic manufacturers avoid the original development cost and rely on the abbreviated pathway, generics typically increase competition and access. The arrival of generics is a structural feature of the pharmaceutical industry’s lifecycle. This overview explains the category in educational terms and makes no claim about any individual product.
Key facts
At a glance
- Definition: Same active ingredient as an approved brand drug
- Key test: Bioequivalence to the reference product
- Pathway: Abbreviated New Drug Application (ANDA)
- May differ: Excipients, shape, colour — not the active ingredient
- Timing: Usually after brand patents and exclusivity expire
- Quality: Held to the same GMP manufacturing standards
Common questions
FAQ
What is a generic drug?+
A generic drug contains the same active ingredient, strength and dosage form as an approved brand-name product and is shown to be bioequivalent to it. It is usually marketed once the original’s patents expire. This is an educational description of a regulatory category, not advice on which medicine to take.
Is a generic drug identical to the brand version?+
A generic must contain the same active ingredient and be bioequivalent, but it may differ in inactive ingredients, shape or colour. The regulatory requirement is that it performs the same way in the body, not that it is identical in every detail.
What is an ANDA?+
An Abbreviated New Drug Application is the FDA pathway for generic drugs. It is abbreviated because it relies on the safety and efficacy already established for the reference product and instead focuses on demonstrating sameness and bioequivalence.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
